Citius Oncology shares jump 20.51% intraday on strong LYMPHIR adoption, payer coverage, and positive clinical trial results.

Citius Oncology surged 20.51% intraday following a commercial update on LYMPHIR, highlighting strong institutional adoption, payer coverage for 80% of lives, and early clinical validation in combination therapies. The company reported 83% of target accounts added LYMPHIR to formularies, repeat orders from leading centers, and advancing investigator-led trials, including positive data in relapsed/refractory lymphoma and gynecologic cancers. These developments signaled growing market confidence in LYMPHIR’s commercial potential and clinical versatility, driving a sharp intraday rally.